Myra Vision, a parent company of Shifamed, has successfully raised $25 million in Series B financing. The funding round was led by Cormorant Asset Management, with significant participation from The Capital Partnership (TCP), the PA MedTech VC Fund, and angel investors from Shifamed. The capital will be utilized to advance product development, scale manufacturing capabilities, and facilitate the first-in-human investigation of Myra Vision’s Calibreye™ System. This innovative system aims to optimize the reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.
Glaucoma is a prevalent cause of blindness, affecting approximately 66 million individuals globally. A significant portion of glaucoma patients, around one-third, have moderate to advanced stages of the condition, necessitating substantial reductions in IOP. Traditionally, surgical procedures such as trabeculectomy and tube shunt implants have been employed to treat these patients. However, newer and less invasive surgical devices have emerged, offering simpler and safer treatment options. Despite the advances, achieving the necessary IOP reductions for patients with moderate to advanced glaucoma remains a challenge.
The Calibreye System developed by Myra Vision is designed to enable physicians to safely optimize aqueous outflow and effectively address the evolving clinical requirements of each patient. The recent funding round reflects strong support from investors, and Myra Vision is excited to continue progressing towards delivering this significant solution for glaucoma patients. The company aims to fill the gap in the market by providing a controlled and personalized approach to surgical treatment for the underserved segment of the glaucoma population.
